Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 10/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367357 | 0.84 | KIF11 (0.44) | CASRKMT2AMEN1ALDH1A1KCNH2 | |
| SCHEMBL4374354 | 0.81 | MAPT (0.48) | CASRMAPTKMT2AMEN1CYP2D6 | |
| SCHEMBL4374348 | 0.81 | MAPT (0.48) | CASRMAPTKMT2AMEN1CYP2D6 | |
| SCHEMBL4366632 | 0.79 | CASR (0.50) | CASRMAPTKMT2AMEN1ADRB2 | |
| SCHEMBL12762284 | 0.77 | KCNN4 (0.48) | ALDH1A1KCNH2 | |
| SCHEMBL19522241 | 0.77 | SLC6A1 (0.44) | MAPTKMT2AMEN1KCNH2 | |
| SCHEMBL4363002 | 0.76 | KIF11 (0.49) | MAPTKMT2AMEN1GAAALDH1A1 | |
| SCHEMBL12225852 | 0.76 | KIF11 (0.49) | MAPTKMT2AMEN1GAAALDH1A1 | |
| SCHEMBL14356107 | 0.75 | KIF11 (0.49) | KMT2AMEN1GAAALDH1A1KCNH2 | |
| SCHEMBL30610089 | 0.75 | KIF11 (0.49) | KMT2AMEN1GAAALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1908829-B1 | OLIGONUCLEOTIDE PROBE | NAT INST OF ADVANCED IND SCIEN (JP) | 2014-01-08 | — | — | EP | disclosed |
| US-7491857-B2 | Oligonucleotide probe | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20080227968-A1 | Oligonucleotide Probe | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-09-18 | — | — | US | disclosed |
| EP-1908829-A1 | OLIGONUCLEOTIDE PROBE | National Institute of Advanced Industrial Science and Technology (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227968-A1 | Oligonucleotide Probe | APEX1, RNGTT, RNASEH1 | CASR 2347/4885MAPT 4572/4885KMT2A 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.